Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 4 , Pages 327-338 , Winter 2009

Therapeutic Sentinel Lymph Node Imaging

References 

  1. Liptay M. Sentinel node mapping in lung cancer. Ann Surg Oncol. 2004;11:271S–274S
  2. Flores R, Park B, Dycoco J, et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg. 2009;138:11–18
  3. Ayabe T, Tomita M, Matsuzaki Y, et al. Micrometastasis and expression of nm23 messenger RNA of lymph nodes from lung cancer and the postoperative clinical outcome. Ann Thorac Cardiovasc Surg. 2004;10:152–159
  4. Benlloch S, Galbis-Caravajal JM, Alenda C, et al. Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): Prognostic impact and potential role as markers of occult micrometastases. Ann Oncol. 2009;20:91–97
  5. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553
  6. Morton D, Thompson J, Cochran A, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–1317
  7. Liptay M, Grondin S, Fry W, et al. Intraoperative sentinel lymph node mapping in non-small-cell lung cancer improves detection of micrometastases. J Clin Oncol. 2002;20:1984–1988
  8. Rzyman W, Hagen O, Dziadziuszko R, et al. Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients. Ann Thorac Surg. 2006;82:237–242
  9. Liptay M, D'Amico T, Nwogu C, et al. Intraoperative sentinel node mapping with technitium-99 in lung cancer: Results of CALGB 140203 multicenter phase II trial. J Thorac Oncol. 2009;4:198–202
  10. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399
  11. Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–398discussion 398-401
  12. Jain R, Dandekar P, Patravale V. Diagnostic nanocarriers for sentinel lymph node imaging. J Control Release. 2009;138:90–102
  13. Schulze T, Bembenek A, Schlag PM. Sentinel lymph node biopsy progress in surgical treatment of cancer. Langenbecks Arch Surg. 2004;389:532–550
  14. Soltesz EG, Kim S, Laurence RG, et al. Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg. 2005;79:269–277discussion 269-277
  15. Song L, Kim C, Maslov K, et al. High-speed dynamic 3D photoacoustic imaging of sentinel lymph node in a murine model using an ultrasound array. Med Phys. 2009;36:3724–3729
  16. Phillips WT, Klipper R, Goins B. Use of (99m)Tc-labeled liposomes encapsulating blue dye for identification of the sentinel lymph node. J Nucl Med. 2001;42:446–451
  17. Nwogu CE, Kanter PM, Anderson TM. Pulmonary lymphatic mapping in dogs: Use of technetium sulfur colloid and isosulfan blue for pulmonary sentinel lymph node mapping in dogs. Cancer Invest. 2002;20:944–947
  18. Wisner ER, Ferrara KW, Short RE, et al. Sentinel node detection using contrast-enhanced power Doppler ultrasound lymphography. Invest Radiol. 2003;38:358–365
  19. Kobayashi H, Kawamoto S, Sakai Y, et al. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst. 2004;96:703–708
  20. Ueno H, Hihara J, Shimizu K, et al. Experimental study on fluorescent microspheres as a tracer for sentinel node detection. Anticancer Res. 2005;25:821–825
  21. Parungo CP, Colson YL, Kim SW, et al. Sentinel lymph node mapping of the pleural space. Chest. 2005;127:1799–1804
  22. Troyan SL, Kianzad V, Gibbs-Strauss SL, et al. The FLARE intraoperative near-infrared fluorescence imaging system: A first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol. 2009;16:2943–2952
  23. Koyama Y, Talanov VS, Bernardo M, et al. A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging. 2007;25:866–871
  24. Vakoc BJ, Lanning RM, Tyrrell JA, et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med. 2009;15:1219–1223
  25. Mulshine JL, Keenan AM, Carrasquillo JA, et al. Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: A new approach to lung cancer imaging. Cancer Res. 1987;47:3572–3576
  26. Adusumilli PS, Eisenberg DP, Stiles BM, et al. Virally-directed fluorescent imaging (VFI) can facilitate endoscopic staging. Surg Endosc. 2006;20:628–635
  27. Eisenberg DP, Adusumilli PS, Hendershott KJ, et al. Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus. Ann Surg. 2006;243:824–830discussion 830-832
  28. Fujiwara T, Urata Y, Tanaka N. Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents. Front Biosci. 2008;13:1881–1886
  29. Gleysteen JP, Newman JR, Chhieng D, et al. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck. 2008;30:782–789
  30. McElroy M, Hayashi K, Garmy-Susini B, et al. Fluorescent LYVE-1 antibody to image dynamically lymphatic trafficking of cancer cells in vivo. J Surg Res. 2009;151:68–73
  31. Brader P, Kelly K, Gang S, et al. Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET. PLoS One. 2009;4:e4789
  32. Huyn ST, Burton JB, Sato M, et al. A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis. Clin Cancer Res. 2009;15:3126–3134
  33. Bergqvist L, Strand SE, Persson BR. Particle sizing and biokinetics of interstitial lymphoscintigraphic agents. Semin Nucl Med. 1983;13:9–19
  34. Alazraki NP, Eshima D, Eshima LA, et al. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med. 1997;27:55–67
  35. Bar J, Herbst RS, Onn A. Targeted drug delivery strategies to treat lung metastasis. Expert Opin Drug Deliv. 2009;6:1003–1016
  36. Dieter M, Schubert R, Hirnle P. Blue liposomes for identification of the sentinel lymph nodes in pigs. Lymphology. 2003;36:39–47
  37. Hirnle P, Harzmann R, Wright JK. Patent blue V encapsulation in liposomes: Potential applicability to endolymphatic therapy and preoperative chromolymphography. Lymphology. 1988;21:187–189
  38. Pump B, Hirnle P. Preoperative lymph-node staining with liposomes containing patent blue violet (A clinical case report). J Pharm Pharmacol. 1996;48:699–701
  39. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006;95:822–828
  40. Ross RW, Zietman AL, Xie W, et al. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging. 2009;33:301–305
  41. Kim S, Lim YT, Soltesz EG, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol. 2004;22:93–97
  42. Ballou B, Ernst LA, Andreko S, et al. Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug Chem. 2007;18:389–396
  43. Dahan M, Laurence T, Pinaud F, et al. Time-gated biological imaging by use of colloidal quantum dots. Opt Lett. 2001;26:825–827
  44. Parungo CP, Ohnishi S, Kim SW, et al. Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J Thorac Cardiovasc Surg. 2005;129:844–850
  45. Dômont J, Soria JC, Le Chevalier T. Adjuvant chemotherapy in early-stage non-small cell lung cancer. Semin Oncol. 2005;32:279–283
  46. Fischer-Brugge E, Sunder-Plassmann P, Roper K. On the terminal innervation of the lymphatic vessels of the appendix, and observations on cellular processes of the blood-lymph barrier in human appendicitis. Langenbecks Arch Klin Chir Ver Dtsch Z Chir. 1950;265:120–132
  47. Grotte G. Passage of dextran molecules across the blood-lymph barrier. Acta Chir Scand Suppl. 1956;211:1–84
  48. Grotte G, Juhlin L, Sandberg N. Passage of solid spherical particles across the blood-lymph barrier. Acta Physiol Scand. 1960;50:287–293
  49. Olszewski W. Lymph Stasis: Pathophysiology, Diagnosis, and Treatment. Boca Raton, FL: CRC Press; 1991;
  50. Matsuzaki K, Natsuda Y, Kai H, et al. Transnodal cancer chemotherapy for metastatic lymph nodes in rats. Cancer Treat Rep. 1987;71:235–239
  51. Lu B, Xiong SB, Yang H, et al. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci. 2006;28:86–95
  52. Dnne A, Boerner H, Kukula H, et al. Block copolymer carrier systems for translymphatic chemotherapy of lymph node metastases. Anticancer Res. 2007;27:3935–3940
  53. Murakami T, Sawada H, Tamura G, et al. Water-dispersed single-wall carbon nanohorns as drug carriers for local cancer chemotherapy. Nanomedicine. 2008;3:453–463
  54. Cai S, Xie Y, Bagby T, et al. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res. 2008;147:247–252
  55. Liu J, Meisner D, Kwong E, et al. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res. 2009;69:1174–1181
  56. Adusumilli P, Chan MK, Hezel M, et al. Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol. 2007;14:258–269
  57. Nakano A, Yoneyama H, Ueha S, et al. Intravenous administration of MIP-1alpha with intra-tumor injection of P. acnes shows potent anti-tumor effect. Int Immunopharmacol. 2007;7:845–857
  58. Prestwich R, Errington F, Ilett E, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res. 2008;14:7358–7366
  59. Yu Z, Li S, Huang YY, et al. Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy. Clin Cancer Res. 2008;14:1897–1904
  60. Qiao J, Kottke T, Willmon C, et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med. 2008;14:37–44
  61. Smith K, Tam V, Wong R, et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine. 2009;27:2603–2615
  62. Hayashi K, Zhao M, Yamauchi K, et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem. 2009;106:992–998
  63. Schder H, Glass E, Pecking A, et al. Molecular targeting of the lymphovascular system for imaging and therapy. Cancer Metastasis Rev. 2006;25:185–201
  64. Hirnle P. Targeted introduction of substances into the lymph nodes for endolymphatic therapy. Cancer Treat Res. 2007;135:101–118
  65. Courtice FC. Lymph flow in the lungs. Br Med Bull. 1963;19:76–79
  66. In:  Charman WN,  Stella VJ editor. Lymphatic Transport of Drugs. Boca Raton, FL: CRC Press; 1992;
  67. Liu J, Wong HL, Moselhy J, et al. Targeting colloidal particulates to thoracic lymph nodes. Lung Cancer. 2006;51:377–386
  68. Choi HS, Seo SA, Khang G, et al. Preparation and characterization of fentanyl-loaded PLGA microspheres: In vitro release profiles. Int J Pharm. 2002;234:195–203
  69. Liu J, Meisner D, Kwong E, et al. A novel trans-lymphatic drug delivery system: Implantable gelatin sponge impregnated with PLGA-paclitaxel microspheres. Biomaterials. 2007;28:3236–3244
  70. Kimura H, Iizasa T, Ishikawa A, et al. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res. 2008;28:1229–1238
  71. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther. 2006;17:1214–1224
  72. Adusumilli PS, Eisenberg DP, Stiles BM, et al. Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus. J Thorac Cardiovasc Surg. 2006;132:1179–1188
  73. Breidenbach M, Rein DT, Everts M, et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 2005;12:187–193
  74. Adusumilli PS, Chan MK, Chun YS, et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther. 2006;5:48–53
  75. Stiles BM, Adusumilli PS, Bhargava A, et al. Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer. Cancer Gene Ther. 2006;13:53–64
  76. Ino Y, Saeki Y, Fukuhara H, et al. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res. 2006;12:643–652
  77. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006;13:975–992
  78. Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res. 2005;11:7444–7453
  79. Wong RJ, Joe JK, Kim SH, et al. Oncolytic herpes virus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther. 2002;13:1213–1223
  80. Pizzato M, Blair ED, Fling M, et al. Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. Gene Ther. 2001;8:1088–1096
  81. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol. 2000;81:2605–2609
  82. Fulci G, Breymann L, Gianni D, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A. 2006;103:12873–12878
  83. Shayakhmetov DM, Gaggar A, Ni S, et al. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol. 2005;79:7478–7491
  84. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129
  85. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99:16168–16173
  86. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13:1440–1449
  87. Qiao J, Wang H, Kottke T, et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther. 2008;15:604–616
  88. Kishimoto H, Kojima T, Watanabe Y, et al. In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. Nat Med. 2006;12:1213–1219
  89. Burton JB, Johnson M, Sato M, et al. Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med. 2008;14:882–888
  90. Kelly KJ, Brader P, Woo Y, et al. Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1 h68 in an immunocompetent animal model. Int J Cancer. 2009;124:911–918
  91. Msaouel P, Iankov ID, Allen C, et al: Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (in press)
  92. Adusumilli PS, Stiles BM, Chan MK, et al. Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. FASEB J. 2006;20:726–728
  93. Adusumilli PS, Chan MK, Hezel M, et al. Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol. 2007;14:258–269
  94. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21:215–223
  95. Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32:169–180
  96. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426–5435
  97. Riviere I, Sadelain M, Brentjens RJ. Novel strategies for cancer therapy: The potential of genetically modified T lymphocytes. Curr Hematol Rep. 2004;3:290–297
  98. Radu CG, Shu CJ, Nair-Gill E, et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2′-deoxycytidine analog. Nat Med. 2008;14:783–788
  99. Matsui K, Wang Z, McCarthy TJ, et al. Quantitation and visualization of tumor-specific T cells in the secondary lymphoid organs during and after tumor elimination by PET. Nucl Med Biol. 2004;31:1021–1031

 Supported in part by AACR-AstraZeneca Lung Cancer Translational Research Grant, AATS-Third Edward D. Churchill Research Scholarship, IASLC−International Association for the Study of Lung Cancer Young Investigator Award, and National Lung Cancer Partnership/LUNGevity Foundation Research Grants.

PII: S1043-0679(09)00138-5

doi: 10.1053/j.semtcvs.2009.11.002

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 4 , Pages 327-338 , Winter 2009

Article Tools

* Image Usage & Resolution